Shitanshu Uppal
Publications Update # 132
Fate of the IP chemotherapy and now the HIPEC chemotherapy, Mirvetuximab + Bevacizumab in ovarian cancer, should we resect para-aortic nodes in locally advanced cervical cancer (video)
Publications Update # 131
Accuracy of sentinel node biopsy for large vulvar tumors, new European guidelines for opportunistic salpingectomy, and the high response rates of pembrolizumab plus lenvatinib for clear cell carcinoma, benefits of ultra-low-dose nivolumab, and the benefits of silence.
PEACOCC: Pembrolizumab in Advanced Clear Cell Gynecological Cancer
Pembrolizumab demonstrated clinical benefit in heavily pretreated advanced CCGC with a tolerable safety profile. Further evaluation in a randomized trial is warranted.
Publications Update # 130
The influence of anxiety, search updates in GYOEDU, knowledge graph, mini-cards for publications update, opportunistic salpingectomy cost-effectiveness, ASCO guidelines - neoadjuvant chemotherapy in ovarian cancer and the futility ofmagnesium replacement
Publications Update # 129
Very low-risk cervical cancer appropriate for MIS simple hysterectomy (video), LASH trial, Pembrolizumab + Lenvatinib in Clear Cell Recurrences, cost-effective ways for genetic testing in ovarian cancer, PARP (olaparib) dose reductions and GYOEDU reminders
LARA: Pembrolizumab plus Lenvatinib in Recurrent Gynaecological Clear Cell Carcinoma
Pembrolizumab plus lenvatinib demonstrated promising anti-tumor activity with an objective response rate of 40% at 24 weeks in patients with recurrent gynaecological clear cell carcinoma.
GOG 3026: Ribociclib Plus Letrozole in Recurrent Low-Grade Serous Ovarian Carcinoma
Publications Update # 128
How to form and break habits, MMR deficiency, MLH1 promoter hypermethylation, and outcomes, low-grade serous ovarian cancer 3026 trial, and FOLR1 expression in low-grade serous ovarian cancer. Updated video of neuroendocrine tumors.
Publications Update # 127
PORTEC 4A video summary and study summary, management of cancer in pregnancy, Mirvetuximab and occular side effects in real world setting and GYOEDU Launchpad details